Press Release : Roche renews partnership with Sysmex to deliver haematology testing solutions

 
   -- This successful long-running partnership continues to evolve and bring 
      haematology testing innovations to laboratories, globally 
 
   -- The new agreement aims to utilise the IT systems to lead to improved 
      clinical decision making and customer experience 
 
   -- Blood disorders have a high impact, not only for patients but for society 
      as a whole, accounting for a third of all central laboratory tests1 
 
 
   Basel, 25 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today 
announced that, on 14 December, 2020, it signed a Global Business 
Partnership Agreement* (GBP) with Sysmex. Under this new framework, the 
parties renewed their commitment to the long standing Distribution, 
Sales and Service (DSS) agreement, allowing Roche to continue to 
distribute Sysmex haematology products, including instruments and 
reagents.(2) This GBP sees the introduction of an IT Solutions 
Collaboration Agreement. In the newly defined collaboration, the two 
companies have agreed to utilise their respective IT platforms to 
improve customer experience, in the short to mid-term, with a longer 
term ambition to use the IT systems to lead to improved clinical 
decision making. The GBP agreement will run until the end of 2030. 
 
   "Roche is committed to supporting improvements in haematology testing, 
which helps patients with the diagnosis and management of blood diseases, 
as diverse as anemia and leukaemia", said Thomas Schinecker, CEO Roche 
Diagnostics. "Extending our longstanding partnership with Sysmex 
underscores our unique synergy and our objective to offer our customers 
high-quality haematology solutions to improve the testing efficiency in 
central laboratories in hospitals and commercial laboratories, 
ultimately benefiting the millions of patients living with blood 
disorders." 
 
   The burden of blood disorders is very high, not only for patients but 
for society as a whole. Recent studies estimated that, in Europe, 80 
million people suffer from haematological disorders and the economic 
impact of blood disorders in Europe amounts to EUR 23 billion per year, 
mostly in healthcare expenditure. Improved management is a key factor to 
counteract the rise of this economic burden for healthcare and 
society.(3) 
 
   About the Roche and Sysmex partnership 
 
   In 1999, Sysmex and Roche entered into a Distributorship Sales and 
Service Agreement (DSS), under which Roche distributed Sysmex hematology 
products and provided services in overseas markets. This mutually 
beneficial arrangement has since advanced as demands for haematology 
testing have evolved, with greater focus on automation of manual 
processes and streamlining workflow, expanding the utility of 
haematological parameters so as to support diagnosis, monitoring and 
treatment across disease areas, beyond routine testing. In 2018, Roche 
and Sysmex entered into a non-exclusive collaboration agreement to offer 
Total Laboratory Solutions (TLS). This means that customers who want to 
purchase products for clinical chemistry, immunochemistry, and 
hematology testing from one vendor, could do so seamlessly with Roche 
and Sysmex. 
 
   The GBP agreement will allow Roche and Sysmex to deliver tailored 
haematology solutions to new and existing customers, while having the 
benefits of working with a single provider. Streamlining testing 
efficiency and effectiveness are an important part of a laboratory's 
remit. Having the opportunity to integrate the technologies from two 
leading IVD companies, while simultaneously having a single service 
provider, can support laboratories to improve their testing solution and 
service delivery. Utilising a single service provider can simplify 
laboratory workflows, inventory management and service solutions, while 
maintaining access to high-quality, market-leading systems and 
solutions. The partnership will also strive to develop a joint framework 
to ensure and promote connectivity through standardisation of 
cybersecurity measures. 
 
 
 
   About Roche 
 
   Roche is a global pioneer in pharmaceuticals and diagnostics focused on 
advancing science to improve people's lives. The combined strengths of 
pharmaceuticals and diagnostics under one roof have made Roche the 
leader in personalised healthcare -- a strategy that aims to fit the 
right treatment to each patient in the best way possible. 
 
 
 
   Roche is the world's largest biotech company, with truly differentiated 
medicines in oncology, immunology, infectious diseases, ophthalmology 
and diseases of the central nervous system. Roche is also the world 
leader in in vitro diagnostics and tissue-based cancer diagnostics, and 
a frontrunner in diabetes management. 
 
 
 
   Founded in 1896, Roche continues to search for better ways to prevent, 
diagnose and treat diseases and make a sustainable contribution to 
society. The company also aims to improve patient access to medical 
innovations by working with all relevant stakeholders. More than thirty 
medicines developed by Roche are included in the World Health 
Organization Model Lists of Essential Medicines, among them life-saving 
antibiotics, antimalarials and cancer medicines. Moreover, for the 
twelfth consecutive year, Roche has been recognised as one of the most 
sustainable companies in the Pharmaceuticals Industry by the Dow Jones 
Sustainability Indices (DJSI). 
 
 
 
   The Roche Group, headquartered in Basel, Switzerland, is active in over 
100 countries and in 2019 employed about 98,000 people worldwide. In 
2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 
61.5 billion. Genentech, in the United States, is a wholly owned member 
of the Roche Group. Roche is the majority shareholder in Chugai 
Pharmaceutical, Japan. For more information, please visit 
https://www.globenewswire.com/Tracker?data=uj5KqyhBr2TRdPcqdH2sS6T0sm4WXwDgxv_h3sNTsRA-oCCo5ShIPLJb01pc1mg7UEnHA9Bcx2k7QxvD0dotqw== 
www.roche.com. 
 
 
 
 
 
   *Overview of the Global Business Partnership Agreement (GBP) 
 
   Date of agreement: December 14, 2020 
 
   Content: Stipulates a global partnership between Sysmex and Roche and 
includes three individual agreements (DSS, TLS, and IT Solutions 
Collaboration Agreement) 
 
   Duration: January 1, 2021 through December 31, 2030 (DSS expires on 
August 31, 2026) 
 
   Information contained in this press release is current as of the date of 
the announcement, but may be subject to change without prior notice. 
 
 
 
 
 
   All trademarks used or mentioned in this release are protected by law. 
 
   References 
 
   [1] Roche internal data 
 
   [2] Territories include Greece, South Africa,Finland, Baltic Territory, 
Brazil, Mexico, Chile, Argentina, Uruguay, Colombia, Peru, Ecuador, 
Venezuela, Central America, Australia and New Zealand. 
 
   [3] Green T, Bron D, Chomienne C, Duyvené de Wit T, de Haas F, 
Engert A, Hagenbeek A, Jäger U, MacIntyre E, Muckenthaler M, Smand 
C, Sonneveld P. Costs of haematological disease high and rising. Lancet 
Haematol 2016 
 
 
 
 
 
 
 
   Roche Group Media Relations 
 
   Phone: [phone] / e-mail: 
https://www.globenewswire.com/Tracker?data=WoatQVJJWFf9Zscr2zX_OmUwSyOtyWMRaL9G5y0MJ6jFn0AOlYHSgCwcXHxaH0LHjyMpOqPrAp8pFobBOFlrHc7PRG4WAGOBFw-gjIBj1H8IFFuxk7qiw0vnKVK1eckS 
[e-mail] 
 
 
 
 
 
 
 
 
Dr. Nicolas Dunant                            Patrick Barth 
 Phone: [phone]                       Phone: [phone] 
Dr. Daniel Grotzky                            Karsten Kleine 
 Phone: [phone]                       Phone: [phone] 
Nina Mählitz                             Nathalie Meetz 
 Phone: [phone]                       Phone: [phone] 
Dr. Barbara von Schnurbein 
 Phone: [phone] 
Roche Investor Relations 
Dr. Karl Mahler                               Jon Kaspar Bayard 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]          e-mail: mailto:[e-mail] 
 [e-mail]                         [e-mail] 
--------------------------------------------  ------------------------------------------- 
Dr. Sabine Borngräber                    Dr. Bruno Eschli 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]   e-mail: mailto:[e-mail] 
 [e-mail]                  [e-mail] 
--------------------------------------------  ------------------------------------------- 
Dr. Birgit Masjost                            Dr. Gerard Tobin 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]       e-mail: mailto:[e-mail] 
 [e-mail]                      [e-mail] 
--------------------------------------------  ------------------------------------------- 
 
Investor Relations North America 
Loren Kalm                                    Dr. Lisa Tuomi 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]            e-mail: mailto:[e-mail] 
 [e-mail]                           [e-mail] 
--------------------------------------------  ------------------------------------------- 
 
 
 
 
   Attachment 
 
 
   -- 25012021_MR_partnership with Sysmex_en 
      https://ml-eu.globenewswire.com/Resource/Download/420373e0-f9a0-4667-8aba-e497bad2f7f3

(END) Dow Jones Newswires

January 25, 2021 01:03 ET (06:03 GMT)